92 related articles for article (PubMed ID: 21704093)
1. The efficacy of intracranial PLG-based vaccines is dependent on direct implantation into brain tissue.
Ali OA; Doherty E; Bell WJ; Fradet T; Hudak J; Laliberte MT; Mooney DJ; Emerich DF
J Control Release; 2011 Sep; 154(3):249-57. PubMed ID: 21704093
[TBL] [Abstract][Full Text] [Related]
2. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells.
Herrlinger U; Kramm CM; Johnston KM; Louis DN; Finkelstein D; Reznikoff G; Dranoff G; Breakefield XO; Yu JS
Cancer Gene Ther; 1997; 4(6):345-52. PubMed ID: 9408604
[TBL] [Abstract][Full Text] [Related]
3. Biomaterial-based vaccine induces regression of established intracranial glioma in rats.
Ali OA; Doherty E; Bell WJ; Fradet T; Hudak J; Laliberte MT; Mooney DJ; Emerich DF
Pharm Res; 2011 May; 28(5):1074-80. PubMed ID: 21225320
[TBL] [Abstract][Full Text] [Related]
4. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
5. Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain.
Tseng SH; Hsieh CL; Lin SM; Hwang LH
Cancer Gene Ther; 1999; 6(4):302-12. PubMed ID: 10419048
[TBL] [Abstract][Full Text] [Related]
6. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells.
Okada H; Villa L; Attanucci J; Erff M; Fellows WK; Lotze MT; Pollack IF; Chambers WH
Gene Ther; 2001 Aug; 8(15):1157-66. PubMed ID: 11509946
[TBL] [Abstract][Full Text] [Related]
7. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
8. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression.
Wallenfriedman MA; Conrad JA; DelaBarre L; Graupman PC; Lee G; Garwood M; Gregerson DS; Jean WC; Hall WA; Low WC
J Neurosurg; 1999 Jun; 90(6):1064-71. PubMed ID: 10350253
[TBL] [Abstract][Full Text] [Related]
9. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
10. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
11. MIP-1alpha antagonizes the effect of a GM-CSF-enhanced subcutaneous vaccine in a mouse glioma model.
Herrlinger U; Aulwurm S; Strik H; Weit S; Naumann U; Weller M
J Neurooncol; 2004 Jan; 66(1-2):147-54. PubMed ID: 15015780
[TBL] [Abstract][Full Text] [Related]
12. Effects of syngeneic cellular vaccinations alone or in combination with GM-CSF on the weakly immunogenic F98 glioma model.
Clavreul A; Delhaye M; Jadaud E; Menei P
J Neurooncol; 2006 Aug; 79(1):9-17. PubMed ID: 16575532
[TBL] [Abstract][Full Text] [Related]
13. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma.
von Mehren M; Arlen P; Gulley J; Rogatko A; Cooper HS; Meropol NJ; Alpaugh RK; Davey M; McLaughlin S; Beard MT; Tsang KY; Schlom J; Weiner LM
Clin Cancer Res; 2001 May; 7(5):1181-91. PubMed ID: 11350882
[TBL] [Abstract][Full Text] [Related]
14. Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?
Clive KS; Tyler JA; Clifton GT; Holmes JP; Mittendorf EA; Ponniah S; Peoples GE
Expert Rev Vaccines; 2010 May; 9(5):519-25. PubMed ID: 20450326
[TBL] [Abstract][Full Text] [Related]
15. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
[TBL] [Abstract][Full Text] [Related]
16. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
17. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
18. Identification of immune factors regulating antitumor immunity using polymeric vaccines with multiple adjuvants.
Ali OA; Verbeke C; Johnson C; Sands RW; Lewin SA; White D; Doherty E; Dranoff G; Mooney DJ
Cancer Res; 2014 Mar; 74(6):1670-81. PubMed ID: 24480625
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes.
Sloan AE; Dansey R; Zamorano L; Barger G; Hamm C; Diaz F; Baynes R; Wood G
Neurosurg Focus; 2000 Dec; 9(6):e9. PubMed ID: 16817692
[TBL] [Abstract][Full Text] [Related]
20. Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model.
Lumniczky K; Desaknai S; Mangel L; Szende B; Hamada H; Hidvegi EJ; Safrany G
Cancer Gene Ther; 2002 Jan; 9(1):44-52. PubMed ID: 11916244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]